Aug 07, 2019
Sierra Oncology to Present at the Wedbush PacGrow Healthcare Conference in New York
Jun 05, 2019
Sierra Announces Momelotinib Granted FDA Fast Track Designation
Jun 04, 2019
Sierra Announces FDA Regulatory Clarity for Momelotinib & Design of the MOMENTUM Phase 3 Clinical Trial
Jun 03, 2019
Sierra Holds Analyst & Investor Event for SRA737
Jun 01, 2019
Sierra Announces Promising Preliminary Efficacy in SRA737 Clinical Program & Outlines Potential Path to Registration
May 28, 2019
Sierra Oncology to Present Momelotinib and SRA737 Overview at the Jefferies Global Healthcare Conference in New York
May 15, 2019
Sierra to Present SRA737 Preliminary Clinical Data and Potential Next Steps at ASCO
May 08, 2019
Sierra Oncology Reports First Quarter 2019 Results
May 06, 2019
Sierra Oncology to Attend Two Investor Conferences in May
Apr 03, 2019
Sierra Reports Late-Breaking SRA141 Preclinical Data in Poster at AACR 2019
Apr 01, 2019
Sierra Reports Late-Breaking Preclinical Data for SRA737 Presented at AACR 2019
Feb 28, 2019
Sierra Oncology Reports 2018 Year End Results
Feb 27, 2019
Sierra Oncology Announces Late-Breaking Oral and Poster Presentations at AACR 2019 for SRA737 and SRA141 Preclinical Data
Jan 23, 2019
Sierra Oncology to Present at the DNA Damage Response Therapeutics Summit
Dec 03, 2018
Sierra Oncology Reports Robust Transfusion Independence Rates in Transfusion Dependent Myelofibrosis Patients Treated with Momelotinib
Nov 29, 2018
Sierra Oncology Reports Preclinical Efficacy for Immunotherapy Combination with its Chk1 inhibitor SRA737
Nov 27, 2018
Sierra Oncology to Host Analyst Call Highlighting Clinical Data on Momelotinib's Anemia Benefit
Nov 13, 2018
Sierra Oncology Reports SRA141 Preclinical Efficacy at EORTC-NCI-AACR Symposium
Nov 08, 2018
Sierra Oncology Reports Third Quarter Results
Nov 07, 2018
Sierra Oncology to Present at the Jefferies 2018 London Healthcare Conference